Sezzle Inc vs Smith & Nephew plc — how do they compare? Sezzle Inc trades at $127.88 (market cap $3.95B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 2.8× Sezzle Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sezzle Inc for 15 Days and Smith & Nephew plc for 121 Days on average.
| SEZL | SNN | |
|---|---|---|
Market Cap | $3.95B | $11.10B |
Volume | 550,075 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $188.55 | $37.17 |
52-Week Low | $50.97 | $26.42 |
Typical Hold Time | 15 Days | 121 Days |
Enterprise Value | $3.99B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
SEZL stock trades at $126.61, up 11.21% with strong bullish momentum. The company demonstrates exceptional profitability with 30.35% net income margin and 88.85% ROE, supported by 51.7% revenue growth in Q2 2026. Technical indicators show bullish signals with current price above key support levels, while analyst consensus targets $168.00 representing 32.7% upside potential. Recent product launches including Sezzle Send and SezzleCash are driving user acquisition and platform growth.
SEZL presents compelling growth prospects with robust fundamentals and positive analyst sentiment, though elevated valuation multiples and competitive BNPL market dynamics warrant monitoring. The stock's current technical strength combined with strong earnings beats and institutional accumulation supports continued upside potential, while investors should consider the stock's premium valuation relative to historical norms.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →